Application of GCA neutralizing antibody in preparation of medicine for preventing and / or treating non-alcoholic steatohepatitis

By using GCA neutralizing antibodies and their hybridoma cell lines, the problem of poor efficacy of NASH treatment methods was solved, which significantly improved liver lipid accumulation and inflammatory cell infiltration, delayed the progress of NASH disease, and achieved protection of liver function.

CN119015409APending Publication Date: 2024-11-26XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411058939.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing treatment methods for NASH are poorly effective and the treatment mechanism is unclear, especially in improving lipid metabolism and reducing liver inflammatory response.

Method used

GCA neutralizing antibodies and their hybridoma cell lines were used to improve liver lipid accumulation and inflammatory cell infiltration, and delay the progression of NASH disease course by injecting GCA-Nab antibodies.

Benefits of technology

GCA neutralizing antibodies significantly reduced the liver function damage index in NASH model mice, reduced liver lipid accumulation and inflammatory cell infiltration, had the effect of protecting liver function, and delayed the progress of NASH disease course.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015409A_ABST
    Figure CN119015409A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedicine, designs application of a GCA neutralizing antibody, and particularly discloses application of the GCA neutralizing antibody in preparation of drugs for treating non-alcoholic steatohepatitis, and the amino acid sequence of the GCA neutralizing antibody is shown as SEQ ID No.2. The GCA neutralizing antibody can effectively improve liver lipid accumulation and inflammatory cell infiltration occurring in the NASH disease course, and the GCA neutralizing antibody plays a positive role in improving the liver lipid accumulation in the NASH disease course; the GCA neutralizing antibody can effectively reduce the inflammatory cell infiltration degree in the NASH disease course; the GCA neutralizing antibody has the effect of protecting the liver function in the NASH disease course; therefore, the liver function is protected to a certain extent, and the progress of the NASH disease course is delayed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and provides a use of a GCA neutralizing antibody in the preparation of a medicament for preventing and / or treating non-alcoholic steatohepatitis. Background Art

[0002] Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that can occur without excessive drinking. Its main feature is the accumulation of fat in the liver, which includes simple fatty liver, non-alcoholic steatohepatitis (NASH), and related liver fibrosis, cirrhosis and hepatocellular carcinoma. Therefore, the development of a new, efficient and safe treatment method has become an urgent problem to be solved.

[0003] NASH is a more severe form of NAFLD, with major pathological features including fatty degeneration of hepatocytes (accounting for ≥5%), ballooning lesions and inflammation of liver lobule, etc. Its occurrence is closely related to metabolic risk factors such as obesity, hypertension and diabetes. The pathogenesis of NASH is complex, and lipid metabolism disorders and liver inflammatory response are key factors aggravating the disease. The pathogenesis of NASH is complex, and lipid metabolism disorders and liver inflammatory response are key factors aggravating the disease.

[0004] Grancalcin (GCA) is a member of the Penta-EF-hand (PEF) family of calcium-binding proteins with five EF-hand motifs, namely the GCAneutralizing antibody, which can block the biological activity of GCA. However, there are no reports on the use of GCA-Nab to improve lipid metabolism, reduce liver inflammatory response, and delay the progression of NASH. Summary of the invention

[0005] The technical problem solved by the present invention is that the present invention aims to solve the problems of poor efficacy and unclear treatment mechanism in existing NASH treatment methods, and provide a new use of GCA neutralizing antibodies and hybridoma cell lines thereof. The present application also provides a use of GCA neutralizing antibodies in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty hepatitis

[0006] The technical problem solved by the present invention is achieved by adopting the following technical solutions:

[0007] In a first aspect, the present application provides use of a GCA neutralizing antibody in the preparation of a medicament for non-alcoholic steatohepatitis, wherein the amino acid sequence of the GCA neutralizing antibody is shown in SEQ ID No.2.

[0008] In some optional embodiments, the GCA neutralizing antibody comprises an amino acid sequence having at least 90% or at least 95% sequence identity with the amino acid sequence shown in SEQ ID No.2.

[0009] In some optional embodiments, the GCA neutralizing antibody is secreted by a hybridoma cell line with a deposit number of CCTCCNO: C2021182.

[0010] In some optional embodiments, when preparing a drug for non-alcoholic steatohepatitis, the GCA neutralizing antibody is encoded by a nucleotide sequence as shown in SEQ ID No. 1.

[0011] In some alternative embodiments, the GCA neutralizing antibody amino acid sequence is administered peripherally.

[0012] In some alternative embodiments, the amino acid sequence of the GCA neutralizing antibody is administered by injection.

[0013] In some optional embodiments, the concentration of the GCA neutralizing antibody is 0.4 ug / ul.

[0014] In some optional embodiments, the GCA neutralizing antibody is dispersed in phosphate buffered saline.

[0015] The invention provides a GCA-Nab cell expression system.

[0016] The present invention provides a GCA neutralizing antibody prepared by the GCA-Nab cell expression system.

[0017] The present invention describes a drug using the above-mentioned GCA neutralizing antibody for delaying or treating NASH and improving the conditions of liver lipid accumulation and inflammatory cell infiltration.

[0018] This application has at least the following beneficial effects:

[0019] The GCA neutralizing antibody of the embodiment of the present application can effectively improve the liver lipid accumulation and inflammatory cell infiltration that occur during the course of NASH. The GCA neutralizing antibody can show a positive effect in improving the liver lipid accumulation during the course of NASH; the GCA neutralizing antibody can effectively reduce the degree of inflammatory cell infiltration during the course of NASH; the GCA neutralizing antibody has the effect of protecting liver function during the course of NASH; thereby protecting the liver function to a certain extent and delaying the progression of NASH.

[0020] Biomaterial deposit information:

[0021] The hybridoma cell line of the present invention was deposited in the China Center for Type Culture Collection (CCTCC) on August 3, 2021, with the deposit address being Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province, China, Postal Code 430072, the deposit number being CCTCC NO: C2021182, and the culture name being hybridoma cell line GCA-NAB4. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0023] Figure 1 A schematic diagram showing the statistical results of the significant decrease in the levels of ALT, AST, TG and TC in the serum of NASH model mice fed with HFFC for 24 weeks and NASH model mice fed with MCD for 6 weeks after injection of GCA-NAb treatment according to the embodiment of the present application (n=6);

[0024] Figure 2 A schematic diagram showing the statistical results of the reduction of liver weight and liver-to-body weight ratio in NASH model mice fed with HFFC for 24 weeks after injection of GCA-NAb in the embodiment of the present application (n=6);

[0025] Figure 3 A representative schematic diagram of Oil Red O staining of the liver of NASH model mice induced by HFFC diet and MCD diet in the examples of the present application after injection of GCA-NAb is shown (n=6);

[0026] Figure 4 A representative staining diagram and a statistical result diagram of F4 / 80 and CD11b immunofluorescence experiment are shown for NASH model mice fed with HFFC for 24 weeks according to an embodiment of the present application after injection of GCA-NAb (n=6);

[0027] Figure 5 A representative staining diagram and a statistical result diagram of Ly6g immunohistochemistry experiment after GCA-NAb injection in NASH model mice fed with HFFC for 24 weeks according to the embodiment of the present application are shown (n=6);

[0028] Figure 6 A schematic diagram showing the statistical results of qPCR experiments to detect the mRNA expression of TNF-a, Il1b and Il6 in NASH model mice fed with HFFC for 24 weeks after injection of GCA-NAb in the embodiment of the present application (n=6);

[0029] Figure 7 Shown are the staining schematic diagram and statistical graph of F4 / 80 and CD11b immunofluorescence experiments after GCA-NAb injection in NASH model mice fed with MCD for 6 weeks according to the embodiment of the present application (n=6);

[0030] Figure 8 A schematic diagram of staining and a schematic diagram of statistical results of Ly6g immunohistochemistry experiments after GCA-NAb injection in NASH model mice fed with MCD for 6 weeks according to an embodiment of the present application are shown (n=6);

[0031] Fig. 9 A schematic diagram showing the statistical results of qPCR experiments to detect the mRNA expression of TNF-a, Il1b and Il6 in NASH model mice fed with MCD for 6 weeks after injection of GCA-NAb in the embodiment of the present application (n=6); DETAILED DESCRIPTION

[0032] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments.

[0033] The following is the GCA gene and protein sequence

[0034] GCA gene sequence (SEQ ID No.1):

[0035] ATGCATCATCACCATCACCACCACCATCACCATCTGGAAGTCCTGTTTCAGGGACCCATGGCCTACCCGGGATACGGAGGAGGGTTTGGAAATTTTAGCATTCAGGTGCCAGGAATGCAGATGGGACAGCCAGTGCCAGAAACAGGCCCAGCTATACTCCTCGATGGATACTCTGGGCCAGCATATTCAGACACTTATTCCTCAGCTGGTGACTCCGTGTATACTTACTTCAGTGCTGTTGCTGGACAGGATGGTGAAGTGGATGCTGAAGAACTTCAGAGATGTTTGACACAGTCTGGAATTAATGGAACTTACTCTCCCTTCAGTTTGGAAACCTGCAGAATTATGATTGCCATGTTGGATAGAGATCACACAGGAAAAATGGGATTTAATGCATTCAAAGAGCTATGGGCAGCTCTTAATGCCTGGAAGGAAAACTTCATGACTGTTGATCAAGATGGAAGTGGCACAGTAGAACATCATGAGTTGCGTCAAGCCATTGGTCTTATGGGTTATAGGTTGAGTCCTCAAACATTAACTACTATTGTTAAACGTTATAGCAAGAATGGCAGAATTTTCTTTGATGATTATGTTGCTTGCTGTGTGAAGCTTCGAGCATTGACAGATTTCTTTAGGAAAAGAGACCACTTGCAACAAGGGTCTGCGAATTTCATATATGAC GATTTTTTGCAGGGCACTATGGCAATTTAA。

[0036] GCA neutralizing protein sequence (SEQ ID No.2):

[0037] MHHHHHHHHHHLEVLFQGPMAYPGYGGGFGNFSIQVPGMQMGQPVPETGPAILLDGYSGPAYSDTYSSAGDSVYTYFSAVAGQDGEVDAEELQRCLTQSGINGTYSPFSLETCRIMIAMLDRDHTGKMGFNAFKELWAALNA

[0038] WKENFMTVDQDGSGTVEHHELRQAIGLMGYRLSPQTLTTIVKRYSKNGRIFFDDYVACCVKLRALTDFFRKRDHLQQGSANFIYDDFLQGTMAI.

[0039] Example 1 Preparation of GCA neutralizing antibodies

[0040] The hybridoma cell line GCA-NAB4 with the laboratory preservation number of CCTCC NO: C2021182 and the culture name was transferred into a 100 mL culture bottle, and a certain amount of culture medium (purchased from GIBCO) was regularly added for cell expansion and cultured for 10-12 days.

[0041] The culture was washed with ultrapure water using a Protein A affinity chromatography column, and then equilibrated with an equilibration buffer; the treated hybridoma cell supernatant was loaded onto the affinity chromatography column, and after loading, the column was rinsed with an equilibration buffer. The column was eluted with an elution buffer, and the elution peak was collected, neutralized with a Tris buffer, and desalted to PBS 7.4 to obtain a GCA-NAb neutralizing antibody, referred to as GCA-NAb, whose amino acid sequence includes the amino acid sequence shown in SEQ ID No. 2.

[0042] Example 2

[0043] Construction of NASH mouse model:

[0044] This experiment involved two types of NASH model mice, namely the NASH mouse model induced by feeding a high-fat, fructose, and cholesterol diet (HFFC) for 24 weeks (HFFC-induced NASH) and the NASH mouse model induced by feeding a methionine-and choline-deficient diet (MCD) for 6 weeks (MCD-induced NASH).

[0045] Twelve 8-week-old male C57BL / 6J mice were fed a high-fat, fructose, and cholesterol diet (HFFC) for 24 weeks. After the modeling time, the mouse livers were collected and the liver tissues were scored and judged according to the NAFLD activity score (NAS). A NAS score of ≥5 points was considered a successful modeling.

[0046] Twenty-four 12-week-old male C57BL / 6J mice were fed a methionine-and choline-deficient diet (MCD) for 6 weeks. After the modeling time, the mouse livers were collected and the liver tissues were scored and judged according to the NAFLD activity score (NAS). A NAS score of ≥5 points was considered a successful modeling.

[0047] After successful modeling, the HFFC diet-induced NASH and MCD diet-induced NASH model mice were divided into experimental and control groups, so that each experimental and control group had two modeling mice. The experimental group was injected with GCA-Nab via the tail vein (at a dose of 1 mg / kg body weight, GCA-Nab concentration of 0.4 ug / ul), and the control group was injected with an equal volume of IgGcontrol via the tail vein. Twice a week, the course of treatment was 8 weeks.

[0048] The GCA-Nab neutralizing antibody at a concentration of 0.4ug / ul includes phosphate buffer.

[0049] Effect detection

[0050] 1) The body weight and food intake of mice were closely monitored, and 1-2 mL of blood was collected from the heart at the end of the experiment (8 weeks), and the levels of ALT, AST, TG and TC in the serum of mice were measured by colorimetry to evaluate liver function. The experimental results are shown in Tables 1, 2 and Figure 1 .

[0051] Table 1

[0052]

[0053] Table 1 and Figure 1 The data in Figures A and B show that compared with the PBS-treated control group, the serum AST, ALT, TC and TG levels of HFFC-induced NASH model mice were significantly reduced after tail vein injection of GCA-NAb.

[0054] Table 2

[0055]

[0056] According to Table 2 and Figure 1 From the data in Figures C and D, it can be clearly observed that compared with the control group treated with PBS only, the serum AST, ALT, TC and TG levels of MCD-induced NASH model mice showed a significant downward trend after tail vein injection of GCA-NAb.

[0057] According to Tables 1, 2 and Figure 1The results of the study showed that GCA-Nab has the potential to reduce liver damage that occurs during NASH.

[0058] 2) Mouse body weight and liver weight detection: The results of mouse body weight and liver weight are shown in Table 3 and Figure 2 shown.

[0059] Table 3

[0060] Group Liver weight (g) Liver weight to body weight ratio IgGcontrol 1.902±0.066 0.050±0.001 GCA-Nab 1.785±0.075* 0.047±0.001**

[0061] From Table 3 and Figure 2 It can be seen that compared with the PBS-treated control group, the liver weight and the ratio of liver weight to body weight of HFFC-induced NASH model mice were reduced after tail vein injection of GCA-NAb, indicating that GCA-NAb treatment can reduce liver enlargement in the process of NASH.

[0062] 2) Mouse liver staining: The results of liver oil red O staining are shown in Table 4 and Figure 3 shown.

[0063] Table 4

[0064]

[0065] from Figure 3 According to the results of Oil Red O staining, compared with the control group treated with IgG control, the degree of liver fatty degeneration in HFFC and / or MCD-induced NASH model mice was alleviated and the number of lipid droplets was significantly reduced after tail vein injection of GCA-NAb, indicating that GCA-NAb can improve liver fatty degeneration in NASH mice and reduce liver lipid deposition.

[0066] Comprehensive Table 4 and Figure 3 Based on the results, it can be concluded that GCA-NAb can effectively inhibit hepatic lipid accumulation in the course of NASH.

[0067] 4) Immunofluorescence staining and immunohistochemistry staining:

[0068] Table 5. Immunofluorescence detection results.

[0069] Group <![CDATA[F4 / 80 + cells / HPF]]> <![CDATA[CD11b + cells / HPF]]> IgGcontrol 46.170±3.312 35.330±6.713 GCA-Nab 31.330±5.502** 22.330±3.445**

[0070] From Table 5 and Figure 4 It can be seen through immunofluorescence staining that after HFFC-induced NASH model mice received tail vein injection of GCA-NAb, the number of F4 / 80+ and CD11b+ macrophages in their livers was significantly reduced compared with the control group treated with IgG control, indicating that GCA-NAb can inhibit the infiltration of liver macrophages in HFFC-induced NASH model mice.

[0071] Table 6

[0072] Group <![CDATA[Ly6g + cells / HPF]]> IgGcontrol 21.330±4.509 GCA-Nab 13.000±2.000*

[0073] From Table 6 and Figure 5 It can be seen from immunohistochemical staining that the number of Ly6g-positive neutrophils in the liver of HFFC-induced NASH model mice decreased after tail vein injection of GCA-NAb compared with the control group treated with IgG control, indicating that GCA-NAb can inhibit the infiltration of neutrophils in the liver in HFFC-induced NASH model mice.

[0074] Table 7

[0075] Group Tnf Il1b Il6 PBS 0.988±0.030 0.998±0.050 1.033±0.027 GCA-Nab 0.728±0.035*** 0.736±0.018*** 0.792±0.038**

[0076] From Table 7 and Figure 6 It can be seen that compared with the control group treated with IgG control, the expression levels of liver inflammatory cytokines Tnfa, Il1b and Il6 mRNA in HFFC-induced NASH model mice were significantly reduced after GCA-NAb was injected into the tail vein, indicating that GCA-NAb can inhibit the inflammatory response of the liver in HFFC-induced NASH model mice.

[0077] Table 8

[0078] Group <![CDATA[F4 / 80 + cells / HPF]]> <![CDATA[CD11b + cells / HPF]]> IgGcontrol 39.000±6.693 33.830±4.535 GCA-Nab 27.170±6.178** 23.830±3.545**

[0079] From Table 8 and Figure 7 It can be seen from immunofluorescence staining that the number of F4 / 80+ and CD11b+ macrophages in the liver of MCD-induced NASH model mice significantly decreased after GCA-NAb was injected into the tail vein compared with the control group treated with IgG control, indicating that GCA-NAb can inhibit the infiltration of liver macrophages in MCD-induced NASH model mice.

[0080] Table 9

[0081] Group PBS GCA-Nab Ly6g+cells / HPF 18.330±1.528 10.330±2.082**

[0083] According to Table 9 and Figure 8 The data were analyzed by immunohistochemical staining and found that compared with the control group treated with IgG control, the number of Ly6g-positive neutrophils in MCD-induced NASH model mice showed a downward trend after GCA-NAb was injected into the tail vein. This shows that in MCD-induced NASH model mice, GCA-NAb can inhibit the infiltration of neutrophils in the liver.

[0084] Table 10

[0085] Group Tnf Il1b Il6 PBS 1.015±0.079 1.076±0.100 1.060±0.170 GCA-Nab 0.691±0.107*** 0.758±0.134*** 0.876±0.084*

[0086] From Table 10 and Fig. 9 It can be seen that the relative mRNA expression levels of proinflammatory cytokines Tnfa, Il1b, and Il6 decreased in MCD-induced NASH model mice after tail vein injection of GCA-NAb compared with the control group treated with IgG control;

[0087] In summary, according to Table 5-10 and Figure 4-9 The comprehensive analysis of the results showed that GCA-Nab can reduce the degree of inflammatory cell infiltration in the course of NASH.

[0088] The values ​​of the above experiments are expressed as the mean ± SD of three tests. *, compared with the control group cells treated with IgG control, P < 0.05; **, compared with the control group cells treated with IgG control, P < 0.01; ***, compared with the control group cells treated with IgG control, P < 0.001.

[0089] The above experiments show that GCA-Nab has a good effect in improving liver lipid accumulation and inflammatory cell infiltration during the course of NASH, thereby effectively protecting liver function.

[0090] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. Use of a GCA neutralizing antibody in the preparation of a medicament for non-alcoholic steatohepatitis, wherein the amino acid sequence of the GCA neutralizing antibody is shown in SEQ ID No.

2.

2. The use according to claim 1, characterized in that The GCA neutralizing antibody comprises an amino acid sequence having at least 90% or at least 95% sequence identity with the amino acid sequence shown in SEQ ID No.

2.

3. The use according to claim 1, characterized in that The GCA neutralizing antibody is secreted by a hybridoma cell line with a deposit number of CCTCC NO: C2021182.

4. The use according to claim 1, characterized in that When preparing a drug for non-alcoholic steatohepatitis, the nucleotide sequence shown in SEQ ID No. 1 is used to encode the GCA neutralizing antibody.

5. The use according to any one of claims 1 to 5, characterized in that: The amino acid sequence of the GCA neutralizing antibody is peripherally administered.

6. The use according to any one of claims 1 to 5, characterized in that: The amino acid sequence of the GCA neutralizing antibody is administered by injection.

7. The use according to any one of claims 1 to 5, characterized in that: The concentration of the GCA neutralizing antibody is 0.4ug / ul.

8. The use according to any one of claims 1 to 5, characterized in that: The GCA neutralizing antibody is dispersed in phosphate buffered saline.